3652 results for «231»
3652 results
Diversity in coronary artery disease treatment
22 May 2026 – From EuroPCR 2026
Focusing on the diversity in coronary artery disease treatment, this session highlights challenges ranging from maintaining interventional cardiology services during conflict to the influence of comorbidities such as type 2 diabetes mellitus on prognosis and risk assessment. It also presents clinical outcomes related to stent thrombosis...
The microcirculation: the next frontier in coronary practice
18 May 2026 – From EuroPCR 2026
Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.
News from drug-eluting therapies in 2026
19 May 2026 – From EuroPCR 2026
This session presents the latest advancements in drug-eluting therapies for 2026, including predictors of target lesion failure after drug-coated balloon treatment, clinical outcomes related to stenting length, and novel insights into sirolimus transfer evidenced by in vivo OCT imaging.
TAVI complications: impact and improvement
20 May 2026 – From EuroPCR 2026
This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.
INOCA/ANOCA: technical aspects
20 May 2026 – From EuroPCR 2026
This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...
Continual refinement in LAA closure
20 May 2026 – From EuroPCR 2026
This session presents the latest advancements in left atrial appendage closure (LAAC). It covers new risk scoring systems, sex-specific outcome analyses, safety in elderly populations, and comparative data between LAMBRE and WATCHMAN devices from a high-volume center, highlighting continual refinement in LAAC strategies.
CTO ADVANCED Level III: LIVE Educational Cases from Institut Cardiovasculaire Paris Sud, France & University Hospital Basel, Switzerland
21 May 2026 – From EuroPCR 2026
This advanced educational session features live complex chronic total occlusion (CTO) PCI cases from Institut Cardiovasculaire Paris Sud and University Hospital Basel. It emphasizes optimizing strategy selection, procedural efficiency across diverse CTO anatomies, and integrating advanced techniques into routine complex practice.
CTO ADVANCED Level I: LIVE Educational Cases from Institut Cardiovasculaire Paris Sud, France & University Hospital Basel, Switzerland
21 May 2026 – From EuroPCR 2026
This advanced level I CTO session features live educational cases from Institut Cardiovasculaire Paris Sud and University Hospital Basel, focusing on structured procedure analysis, imaging-based planning, and integrated CTO techniques. Detailed case presentations and live procedural demonstrations underscore strategies for success in complex CTO interventions.
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
